AstraZeneca (AZN.US) has significantly extended the life of cancer patients with its groundbreaking immunotherapy combination Imfinzi.
Imfinzi is a humanized monoclonal antibody.
Express News | Trump Order Halts Funding For School Covid Vaccine Mandates
AstraZeneca Reports Positive Results for Imfinzi MIBC Regimen
AstraZeneca's Bladder Cancer Combo Therapy Shows Efficacy in Late-stage Study
Fund Update: UBS AM, a Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Opened a $12.0M Position in $AZN Stock
AstraZeneca's IMFINZI Perioperative Regimen Improved Event-Free Survival And Overall Survival Across Muscle-Invasive Bladder Cancer Patients Regardless Of Complete Pathology Response Status In Post-Hoc Exploratory Analysis Of Niagara Phase III Trial
IMFINZI (Durvalumab) Perioperative Regimen Improved Event-free Survival and Overall Survival Across Muscle-invasive Bladder Cancer Patients Regardless of Complete Pathology Response Status in Post-hoc Exploratory Analysis of NIAGARA Phase III Trial
Roche Upgraded by UBS to Buy on Growth Outlook
Market Chatter: RFK Jr. Confirmed as HHS Head by Senate
Fund Update: Phoenix Financial Ltd. Just Disclosed New Holdings
PhaseV Launches Webinar Series on AI and Data-Driven Clinical Trial Optimization
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
AstraZeneca Analyst Ratings
AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk
AstraZeneca Target Raised to GBP142.00 From GBP115.00 by UBS
AstraZeneca Raised to Buy From Neutral by UBS
AstraZeneca Seen Posting Double-Digit Earnings Growth in 2025, Morgan Stanley Says
Trade Desk, Leidos, Devon Energy And A Major Health Care Stock On CNBC's 'Final Trades'
Deutsche Bank Sticks to Their Hold Rating for AstraZeneca (AZN)
Morgan Stanley Kicks Off AstraZeneca at Overweight